What were the results of the PROTECT AF trial evaluating the WATCHMAN device?
The efficacy of LAA closure with the WATCHMAN device met the pre-specified criteria for non-inferiority compared to warfarin, but the rate of adverse safety events in the intervention group was 4.4% with evidence of harmful periprocedural complications (pericardial effusion and procedure-related ischemic stroke).